Document Detail

Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
MedLine Citation:
PMID:  16154634     Owner:  NLM     Status:  MEDLINE    
The study was conducted to determine whether the expression of behavioral supersensitivity induced by haloperidol (HAL) administered once daily (2 mg/kg i.p.) for 14 days is associated with the alterations in activity of neuropeptide Y (NPY) system in the striatum (caudate-putamen) and nucleus accumbens. Dopamine supersensitivity was tested by measurement of locomotor activity and stereotyped behavior after administration of the dopamine D2/D3 receptor agonist quinpirole (1 mg/kg i.p.) on day 1, 3 and 7 after HAL withdrawal. Neuropeptide Y-like immunoreactivity (NPY-LI) was determined in the striatum and nucleus accumbens isolated 6 h after quinpirole injection on day 1, 3 and 7 after the end of HAL treatment. NPY mRNA was quantified in these structures on day 7 after HAL withdrawal. HAL increased spontaneous locomotor activity and prevalence of rearing, grooming and head-down sniffing. At the same time, striatal NPY-LI increased progressively from the reduced level found on day 1 of haloperidol withdrawal. NPY mRNA remained unchanged. In saline-treated rats, quinpirole enhanced locomotion, rearing, and induced intense head-down sniffing and oral activity. These behavioral effects were accompanied by a decrease in striatal NPY-LI. NPY mRNA was slightly increased. HAL treatment altered response to quinpirole, namely it increased locomotion, intensified oral activity and reduced rearing and head-down sniffing. The second and the third quinpirole injection decreased NPY-LI levels. NPY mRNA was unchanged. In the nucleus accumbens, apart from a decrease in NPY-LI on day 1 after the last haloperidol dose, the level of NPY-LI and NPY mRNA in any experimental group did not differ from the control value. The presented results suggest that the alterations in the activity of the striatal but not nucleus accumbens NPY system contribute to adaptive changes induced by long-term haloperidol treatment and may be of significance to the motor hyperactivity induced by intermittent stimulation of postsynaptic dopamine D2 receptors.
E Obuchowicz; R Krysiak; J M Wieronska; M Smialowska; Z S Herman
Related Documents :
8265684 - Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms.
18703024 - Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and gl...
12873624 - Effect of repeated administration of phencyclidine on spatial performance in an eight-a...
2995054 - Chronic haloperidol causes increase in salivary response and alpha 1-adrenoceptors in s...
18686134 - Imaging of 186re-liposome therapy in ovarian cancer xenograft model of peritoneal carci...
2591524 - The effect of l-dopa upon in vitro dopamine release from the corpus striatum of young a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-09-09
Journal Detail:
Title:  Neuropeptides     Volume:  39     ISSN:  0143-4179     ISO Abbreviation:  Neuropeptides     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-17     Completed Date:  2006-02-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8103156     Medline TA:  Neuropeptides     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  515-23     Citation Subset:  IM    
Department of Clinical Pharmacology, Silesian University School of Medicine, Medykow 18 Street, 40-752 Katowice, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Behavior, Animal / drug effects*
Corpus Striatum / cytology,  drug effects*,  metabolism
Dopamine Agonists / pharmacology
Dopamine Antagonists / pharmacology*
Haloperidol / pharmacology*
In Situ Hybridization
Motor Activity / drug effects*
Neuropeptide Y / genetics,  metabolism*
Quinpirole / pharmacology
RNA, Messenger / metabolism
Rats, Wistar
Reg. No./Substance:
0/Dopamine Agonists; 0/Dopamine Antagonists; 0/Neuropeptide Y; 0/RNA, Messenger; 52-86-8/Haloperidol; 85760-74-3/Quinpirole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Collagen composite hydrogels for vocal fold lamina propria restoration.
Next Document:  Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease).